Epigallocatechin Gallate has a neurorescue effect in a mouse model of Parkinson disease

Journal of Nutrition

Volumn 147, Issue 10, 2017, Pages 1926-1931

  Xu, Qi ^a,b   Langley, Monica ^a   Kanthasamy, Anumantha G ^a   Reddy, Manju B ^a  

^a IOWA STATE UNIVERSITY   (United States)

^b SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

EGCG; Ferroportin; MPTP; Oxidative stress; Parkinson disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DIHYDROXYPHENYLACETIC ACID; DOPAMINE; EPIGALLOCATECHIN GALLATE; FERROPORTIN; HEPCIDIN; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; PLASMA PROTEIN; ANTIOXIDANT; CATECHIN; CATION TRANSPORT PROTEIN; IRON; METAL TRANSPORTING PROTEIN 1; NEUROPROTECTIVE AGENT; PHENYLACETIC ACID; PHENYLACETIC ACID DERIVATIVE; PLANT EXTRACT; SOLUTE CARRIER FAMILY 11- (PROTON-COUPLED DIVALENT METAL ION TRANSPORTERS), MEMBER 2; TEA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; LATENT PERIOD; LOCOMOTION; MALE; MOTOR COORDINATION; MOUSE; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN EXPRESSION; STRIATE CORTEX; SUBSTANTIA NIGRA; WEIGHT GAIN; ANALOGS AND DERIVATIVES; ANIMAL; ANIMAL BEHAVIOR; C57BL MOUSE; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; METABOLISM; MOTOR ACTIVITY; PATHOPHYSIOLOGY; PHYTOTHERAPY; PROTEIN CARBONYLATION; TEA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTIOXIDANTS; BEHAVIOR, ANIMAL; BLOOD PROTEINS; CATECHIN; CATION TRANSPORT PROTEINS; DISEASE MODELS, ANIMAL; DOPAMINE; HEPCIDINS; IRON; MALE; MICE, INBRED C57BL; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PARKINSON DISEASE; PHENYLACETATES; PHYTOTHERAPY; PLANT EXTRACTS; PROTEIN CARBONYLATION; SUBSTANTIA NIGRA; TEA;

EID: 85030555334     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.3945/jn.117.255034     Document Type: Article

References (53)

1. Litteljohn D, Mangano E, Clarke M, Bobyn J, Moloney K, Hayley S. Inflammatory mechanisms of neurodegeneration in toxin-based models of Parkinson's disease. Parkinsons Dis 2011;2011:713517.
2. Radad K, Gille G, Rausch WD. Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson's disease. Pharmacol Rep 2005;57:701-12.
3. Urrutia PJ, Menam NP, Núñez MT. The interplay between iron accumulation, mitochondrial dysfunction, and inflammation during the execution step of neurodegenerative disorders. Front Pharmacol 2014;5:38.
4. Dias V, Junn E, MouradianMM. The role of oxidative stress in Parkinson's disease. J Parkinsons Dis 2013;3:461-91.
5. Tansey MG, Goldberg MS. Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 2010;37:510-8.
6. Rathnasamy G, Ling EA, Kaur C. Consequences of iron accumulation in microglia and its implications in neuropathological conditions. CNS Neurol Disord Drug Targets 2013;12:785-98.
7. Lin M, Rippe RA, Niemela O, Brittenham G, Tsukamoto H. Role of iron in NF-kappa B activation and cytokine gene expression by rat hepatic macrophages. Am J Physiol 1997;272:G1355-64.
8. Ayton S, Lei P. Nigral iron elevation is an invariable feature of Parkinson's disease and is a sufficient cause of neurodegeneration. BioMed Res Int 2014;2014:581256.
9. Gelman N, Gorell JM, Barker PB, Savage RM, Spickler EM, Windham JP, Knight RA. MR imaging of human brain at 3.0 T: preliminary report on transverse relaxation rates and relation to estimated iron content. Radiology 1999;210:759-67.
10. Berg D, Becker G, Riederer P, Riess O. Iron in neurodegenerative disorders. Neurotox Res 2002;4:637-53.
11. Mounsey RB, Teismann P. Chelators in the treatment of iron accumulation in Parkinson's disease. Int J Cell Biol 2012;2012:983245.
12. Le W. Role of iron in UPS impairment model of Parkinson's disease. Parkinsonism Relat Disord 2014;20(Suppl 1):S158-61.
13. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306:2090-3.
14. Raha-Chowdhury R, Raha AA, Forostyak S, Zhao JW, Stott SR, Bomford A. Expression and cellular localization of hepcidin mRNA and protein in normal rat brain. BMC Neurosci 2015;16:24.
15. Wang SM, Fu LJ, Duan XL, Crooks DR, Yu P, Qian ZM, Di XJ, Li J, Rouault TA, Chang YZ. Role of hepcidin in murine brain iron metabolism. Cell Mol Life Sci 2010;67:123-33.
16. Meredith GE, Rademacher DJ. MPTP mouse models of Parkinson's disease: an update. J Parkinsons Dis 2011;1:19-33.
17. He Y, Thong PS, Lee T, Leong SK, Mao BY, Dong F, Watt F. Dopaminergic cell death precedes iron elevation in MPTP-injected monkeys. Free Radic Biol Med 2003;35:540-7.
18. Salazar J, Mena N, Hunot S, Prigent A, Alvarez-Fischer D, Arredondo M, Duyckaerts C, Sazdovitch V, Zhao L, Garrick LM, et al. Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease. Proc Natl Acad Sci USA 2008;105:18578-83.
19. Lv Z, Jiang H, Xu H, Song N, Xie J. Increased iron levels correlate with the selective nigral dopaminergic neuron degeneration in Parkinson's disease. J Neural Transm 2011;118:361-9.
20. Levenson CW, Cutler RG, Ladenheim B, Cadet JL, Hare J, Mattson MP. Role of dietary iron restriction in a mouse model of Parkinson's disease. Exp Neurol 2004;190:506-14.
21. Kaur D, Yantiri F, Rajagopalan S, Kumar J, Mo JQ, Boonplueang R, Viswanath V, Jacobs R, Yang L, Beal MF, et al. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 2003;37:899-909.
22. Mandel SA, Amit T, Kalfon L, Reznichenko L, Youdim MB. Targeting multiple neurodegenerative diseases etiologies with multimodal-acting green tea catechins. J Nutr 2008;138:1578S-83S.
23. Tanaka K, Miyake Y, Fukushima W, Sasaki S, Kiyohara C, Tsuboi Y, Yamada T, Oeda T, Miki T, Kawamura N, et al. Intake of Japanese and Chinese teas reduces risk of Parkinson's disease. Parkinsonism Relat Disord 2011;17:446-50.
24. Tomata Y, Sugiyama K, Kaiho Y, Honkura K, Watanabe T, Zhang S, Sugawara Y, Tsuji I. Green tea consumption and the risk of incident dementia in elderly Japanese: the Ohsaki Cohort 2006 Study. Am J Geriatr Psychiatry 2016;24:881-9
25. Mandel S, Amit T, Reznichenko L, Weinreb O, Youdim MB. Green tea catechins as brain-permeable, natural iron chelators-antioxidants for the treatment of neurodegenerative disorders. Mol Nutr Food Res 2006;50:229-34.
26. Ye Q, Ye L, Xu X, Huang B, Zhang X, Zhu Y, Chen X. Epigallocatechin-3-gallate suppresses 1-methyl-4-phenyl-pyridine-induced oxidative stress in PC12 cells via the SIRT1/PGC-1alpha signaling pathway. BMC Complement Altern Med 2012;12:82.
27. Li R, Peng N, Du F, Li XP, Le WD. Epigallocatechin gallate protects dopaminergic neurons against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridineinduced neurotoxicity by inhibiting microglial cell activation. Nan Fang Yi Ke Da Xue Xue Bao 2006;26:376-80.
28. Choi JY, Park CS, Kim DJ, Cho MH, Jin BK, Pie JE, Chung WG. Prevention of nitric oxide-mediated 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced Parkinson's disease in mice by tea phenolic epigallocatechin 3-gallate. Neurotoxicology 2002;23:367-74.
29. Ghosh A, Kanthasamy A, Joseph J, Anantharam V, Srivastava P, Dranka BP, Kalyanaraman B, Kanthasamy AG. Anti-inflammatory and neuroprotective effects of an orally active apocynin derivative in preclinical models of Parkinson's disease. J Neuroinflammation 2012; 9:241.
30. Lynch TL IV, Sivaguru M, Velayutham M, Cardounel AJ, Michels M, Barefield D, Govindan S, Dos Remedios C, van der Velden J, Sadayappan S. Oxidative stress in dilated cardiomyopathy caused by MYBPC3 mutation. Oxid Med Cell Longev 2015;2015:424751.
31. Ngwa HA, Kanthasamy A, Jin H, Anantharam V, Kanthasamy AG. Vanadium exposure induces olfactory dysfunction in an animal model of metal neurotoxicity. Neurotoxicology 2014;43:73-81.
32. Gordon R, Anantharam V, Kanthasamy AG, Kanthasamy A. Proteolytic activation of proapoptotic kinase protein kinase Cdelta by tumor necrosis factor alpha death receptor signaling in dopaminergic neurons during neuroinflammation. J Neuroinflammation 2012;9:82.
33. Walter E, Odin P. Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson's disease in the UK and Germany. J Med Econ 2015;18:155-65.
34. Jankovic J, Aguilar LG. Current approaches to the treatment of Parkinson's disease. Neuropsychiatr Dis Treat 2008;4:743-57.
35. Lan J, Jiang DH. Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice. J Neural Transm 1997; 104:469-81.
36. Xu Q, Kanthasamy AG, Reddy MB. Neuroprotective effect of the natural iron chelator, phytic acid in a cell culture model of Parkinson's disease. Toxicology 2008;245:101-8.
37. Xu Q, Kanthasamy AG, Reddy MB. Phytic acid protects against 6-hydroxydopamine-induced dopaminergic neuron apoptosis in normal and iron excess conditions in a cell culture model. Parkinsons Dis 2011;2011:431068.
38. Liu G, Men P, Perry G, Smith MA. Nanoparticle and iron chelators as a potential novel Alzheimer therapy. Methods Mol Biol 2010;610:123-44.
39. Levine JE, Cohen A, MacQueen M, Martin M, Giardina PJ. Sensorimotor neurotoxicity associated with high-dose deferoxamine treatment. J Pediatr Hematol Oncol 1997;19:139-41.
40. Kaur D, Andersen JK. Ironing out Parkinson's disease: is therapeutic treatment with iron chelators a real possibility? Aging Cell 2002;1:17-21.
41. Kwiatkowski A, Ryckewaert G, Jissendi Tchofo P, Moreau C, Vuillaume I, Chinnery PF, Destee A, Defebvre L, Devos D. Long-term improvement under deferiprone in a case of neurodegeneration with brain iron accumulation. Parkinsonism Relat Disord 2012;18:110-2.
42. Abbruzzese G, Cossu G, Balocco M, Marchese R, Murgia D, Melis M, Galanello R, Barella S, Matta G, Ruffinengo U, et al. A pilot trial of deferiprone for neurodegeneration with brain iron accumulation. Haematologica 2011;96:1708-11.
43. Levites Y, Amit T, Youdim MB, Mandel S. Involvement of protein kinase C activation and cell survival/cell cycle genes in green tea polyphenol (2)-epigallocatechin 3-gallate neuroprotective action. J Biol Chem 2002;277:30574-80.
44. Levites Y, Weinreb O, Maor G, Youdim MB, Mandel S. Green tea polyphenol (2)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced dopaminergic neurodegeneration. J Neurochem 2001;78:1073-82.
45. Potashkin JA, Blume SR, Runkle NK. Limitations of animal models of Parkinson's disease. Parkinsons Dis 2010;2011:658083.
46. Chen D, Zhou Y, Lyons KE, Reddy MB. Green tea consumption reduces oxidative stress in Parkinson's disease patients. JBBS 2015;5:194-202.
47. Ward DM, Kaplan J. Ferroportin-mediated iron transport: expression and regulation. Biochim Biophys Acta 2012;1823: 1426-33.
48. Pantopoulos K, Hentze MW. Rapid responses to oxidative stress mediated by iron regulatory protein. EMBO J 1995;14:2917-24.
49. LazzaroM, Bettegazzi B, BarbarigaM, Codazzi F, Zacchetti D, AlessioM. Ceruloplasmin potentiates nitric oxide synthase activity and cytokine secretion in activated microglia. J Neuroinflammation 2014;11:164.
50. Chen D, Kanthasamy A, Reddy MB. EGCG protects against 6-OHDAinduced neurotoxicity in a cell culture model. Parkinsons Dis 2015; 2015:843906.
51. You LH, Li F, Wang L, Zhao SE, Wang SM, Zhang LL, Zhang LH, Duan XL, Yu P, Chang YZ. Brain iron accumulation exacerbates the pathogenesis of MPTP-induced Parkinson's disease. Neuroscience 2015; 284:234-46.
52. Reagan-Shaw S, Nihal M. Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008;22:659-61.
53. Morin MP, Bedran TB, Fournier-Larente J, Haas B, Azelma J, Grenier D. Green tea extract and its major constituent epigallocatechin-3-gallate inhibit growth and halitosis-related properties of Solobacterium moorei. BMC Complement Altern Med 2015;15:48.